Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515442 | PMC |
| http://dx.doi.org/10.1016/j.euf.2023.06.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer.
Ther Adv Urol
September 2025
Department of Urology, Peking University People's Hospital, 11 Xizhimen South Street, Haidian District, Beijing 100044, China.
Objective: Many studies have stressed the necessity of repeat transurethral resection (reTURB) following the initial conventional transurethral resection of the bladder for non-muscle invasive bladder cancer (NMIBC) patients. However, there have been few studies focusing on the role of reTURB after en bloc resection of bladder tumor (ERBT) for NMIBC by far. This study aimed to evaluate whether reTURB can be avoided after ERBT.
View Article and Find Full Text PDFCT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two Years after TURBT.
Curr Med Imaging
May 2025
Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Background: Predicting the recurrence risk of NMIBC after TURBT is crucial for individualized clinical treatment.
Objective: The objective of this study is to evaluate the ability of radiomic feature analysis of intratumoral and peritumoral regions based on computed tomography (CT) imaging to predict recurrence in non-muscle-invasive bladder cancer (NMIBC) patients who underwent transurethral resection of bladder tumor (TURBT).
Methods: A total of 233 patients with NMIBC who underwent TURBT were retrospectively analyzed.
Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.
Int J Cancer
September 2025
Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.
Bladder cancer (BlCa) exhibits a highly heterogeneous molecular landscape and treatment response, underlining the pressing need for personalized prognosis. N6-methyladenosine (m6A) constitutes the most abundant RNA modification, modulates RNA biology/metabolism, and maintains cellular homeostasis, with its dysregulation involved in cancer initiation and progression. Herein, we evaluated the clinical value of METTL3 m6A methyltransferase, the main catalytic component of m6A methylation machinery, in improving BlCa patients' risk stratification and prognosis.
View Article and Find Full Text PDFCu(OH)PO@PAA Nanoparticles for Highly Effective Combination of Chemodynamic, Photodynamic and Photothermal Therapies Against Bladder Cancer.
Int J Nanomedicine
September 2025
Department of Ultrasonic Imaging, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, People's Republic of China.
Background: Due to the complex structure and variable microenvironment in the progression of bladder cancer, the efficacy of traditional treatment methods such as surgery and chemotherapy is limited. Tumor residual, recurrence and metastasis are still difficult to treat. The integration of diagnosis and treatment based on nanoparticles can offer the potential for precise tumor localization and real-time therapeutic monitoring.
View Article and Find Full Text PDF